精神心理科指南

订阅

MedSci主页 / 所有栏目 / 精神心理科指南

2017 佛罗里达最佳实践指南：成人抑郁症的药物治疗

2017-06-10 国外精神科相关专家小组（统称） J Clin Psychiatry. 2017 Jun;78(6):703-713.

药物治疗抑郁症

2017年，佛罗里达专家工作组（Florida Expert Panel）对2015年版的佛罗里达精神科药物治疗最佳实践指南（FPG）——成人抑郁症部分进行了修订。 指南对规范化诊疗、基于量化的治疗、全面评估及总体躯体/精神健康的管理进行了强调。证据重视抑郁标注（Specifiers，如混合特征、焦虑痛苦等）及药物遗传学（及其他生物行为标记物）在指导治疗决策选择中的意义。

中文标题：

2017 佛罗里达最佳实践指南：成人抑郁症的药物治疗

英文标题：

Florida Best Practice Psychotherapeutic Medication Guidelines for Adults With Major Depressive Disorder.

发布机构：

国外精神科相关专家小组（统称）

发布日期：

2017-06-10

简要介绍：

2017年，佛罗里达专家工作组（Florida Expert Panel）对2015年版的佛罗里达精神科药物治疗最佳实践指南（FPG）——成人抑郁症部分进行了修订。 指南对规范化诊疗、基于量化的治疗、全面评估及总体躯体/精神健康的管理进行了强调。证据重视抑郁标注（Specifiers，如混合特征、焦虑痛苦等）及药物遗传学（及其他生物行为标记物）在指导治疗决策选择中的意义。

 

拓展指南：与抑郁症相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2017 佛罗里达最佳实践指南：成人抑郁症的药物治疗)] GetToolGuiderByIdResponse(projectId=1, id=6992d1c001a89662, title=2017 佛罗里达最佳实践指南：成人抑郁症的药物治疗, enTitle=Florida Best Practice Psychotherapeutic Medication Guidelines for Adults With Major Depressive Disorder., guiderFrom=J Clin Psychiatry. 2017 Jun;78(6):703-713., authorId=null, author=, summary=2017年，佛罗里达专家工作组（Florida Expert Panel）对2015年版的佛罗里达精神科药物治疗最佳实践指南（FPG）——成人抑郁症部分进行了修订。 指南对规范化诊疗、基于量化的治疗、全面评估及总体躯体/精神健康的管理进行了强调。证据重视抑郁标注（Specifiers，如混合特征、焦虑痛苦等）及药物遗传学（及其他生物行为标记物）在指导治疗决策选择中的意义。, cover=, journalId=null, articlesId=null, associationId=1320, associationName=国外精神科相关专家小组（统称）, associationIntro=, copyright=0, guiderPublishedTime=Sat Jun 10 00:00:00 CST 2017, originalUrl=, linkOutUrl=, content=<P>2017年，佛罗里达专家工作组（Florida Expert Panel）对2015年版的佛罗里达精神科药物治疗最佳实践指南（FPG）——成人抑郁症部分进行了修订。 指南对规范化诊疗、基于量化的治疗、全面评估及总体躯体/精神健康的管理进行了强调。证据重视抑郁标注（Specifiers，如混合特征、焦虑痛苦等）及药物遗传学（及其他生物行为标记物）在指导治疗决策选择中的意义。</P> <P> </P>拓展指南：<strong>与<font color=red>抑郁症</font>相关指南：</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=b82b41c001a486c6" title="2017 APA共识建议：重复经颅刺激（rTMS）治疗抑郁症的临床应用" target=_blank>2017 APA共识建议：重复经颅刺激（rTMS）治疗抑郁症的临床应用</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=f8f9d1c001390ec9" title="【专题】 应对抑郁症，让医患“零”压力的神器竟然是这个！！！" target=_blank>【专题】 应对抑郁症，让医患“零”压力的神器竟然是这个！！！</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=c0a951c00128308b" title="2015 BAP循证指南：抗抑郁药治疗抑郁症（修订2008版）" target=_blank>2015 BAP循证指南：抗抑郁药治疗抑郁症（修订2008版）</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=4e7c41c001282998" title="2015 AHA科学声明：重度抑郁症和双相情感障碍会导致年轻人加速性动脉粥样硬化和早期心血管疾病  " target=_blank>2015 AHA科学声明：重度抑郁症和双相情感障碍会导致年轻人加速性动脉粥样硬化和早期心血管疾病  </a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=2f01e1c0012828cc" title="2016 USPSTF建议声明：成人抑郁症筛查  " target=_blank>2016 USPSTF建议声明：成人抑郁症筛查  </a></li> 更多信息请点击：<a href="http://www.medsci.cn/guideline/list.do?q=%E6%8A%91%E9%83%81%E7%97%87" target=_blank>有关抑郁症更多指南</a></ul>, tagList=[TagDto(tagId=1113, tagName=药物治疗), TagDto(tagId=228, tagName=抑郁症)], categoryList=[CategoryDto(categoryId=13, categoryName=精神心理科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=4, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=7046, appHits=395, showAppHits=0, pcHits=4308, showPcHits=3118, likes=164, shares=12, comments=5, approvalStatus=1, publishedTime=Tue Aug 29 19:46:21 CST 2017, publishedTimeString=2017-06-10, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Tue Aug 29 19:46:21 CST 2017, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 11:47:39 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2017 佛罗里达最佳实践指南：成人抑郁症的药物治疗)])
2017 佛罗里达最佳实践指南：成人抑郁症的药物治疗
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2099583, encodeId=dcf1209958367, content=很有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210420/09716af288084795ba128059da55a818/c3137a18601c4c54bb7d71ac97630870.jpg, createdBy=e9985480565, createdName=ozzy, createdTime=Thu Nov 10 11:26:55 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969204, encodeId=98e896920411, content=好文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210528/a0d2a11691b24091b5b9dbfbadf81dc9/2fdf08a8d767479e869c7752c34716dc.jpg, createdBy=c3915509274, createdName=Ineslou, createdTime=Fri May 28 13:38:41 CST 2021, time=2021-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948369, encodeId=a6889483695e, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef3e5469300, createdName=lpengcheng7, createdTime=Mon Mar 15 15:32:09 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901610, encodeId=b2aa90161032, content=好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210906/e141ddca670e4042bffbf47e00f8d2fd/b6517df71dfe42cb979aacdc454225cc.jpg, createdBy=0c532181739, createdName=12074e34m25(暂无昵称), createdTime=Mon Nov 23 23:25:56 CST 2020, time=2020-11-23, status=1, ipAttribution=)]
    2022-11-10 ozzy

    很有收获

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2099583, encodeId=dcf1209958367, content=很有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210420/09716af288084795ba128059da55a818/c3137a18601c4c54bb7d71ac97630870.jpg, createdBy=e9985480565, createdName=ozzy, createdTime=Thu Nov 10 11:26:55 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969204, encodeId=98e896920411, content=好文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210528/a0d2a11691b24091b5b9dbfbadf81dc9/2fdf08a8d767479e869c7752c34716dc.jpg, createdBy=c3915509274, createdName=Ineslou, createdTime=Fri May 28 13:38:41 CST 2021, time=2021-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948369, encodeId=a6889483695e, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef3e5469300, createdName=lpengcheng7, createdTime=Mon Mar 15 15:32:09 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901610, encodeId=b2aa90161032, content=好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210906/e141ddca670e4042bffbf47e00f8d2fd/b6517df71dfe42cb979aacdc454225cc.jpg, createdBy=0c532181739, createdName=12074e34m25(暂无昵称), createdTime=Mon Nov 23 23:25:56 CST 2020, time=2020-11-23, status=1, ipAttribution=)]
    2021-05-28 Ineslou

    好文

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2099583, encodeId=dcf1209958367, content=很有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210420/09716af288084795ba128059da55a818/c3137a18601c4c54bb7d71ac97630870.jpg, createdBy=e9985480565, createdName=ozzy, createdTime=Thu Nov 10 11:26:55 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969204, encodeId=98e896920411, content=好文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210528/a0d2a11691b24091b5b9dbfbadf81dc9/2fdf08a8d767479e869c7752c34716dc.jpg, createdBy=c3915509274, createdName=Ineslou, createdTime=Fri May 28 13:38:41 CST 2021, time=2021-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948369, encodeId=a6889483695e, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef3e5469300, createdName=lpengcheng7, createdTime=Mon Mar 15 15:32:09 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901610, encodeId=b2aa90161032, content=好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210906/e141ddca670e4042bffbf47e00f8d2fd/b6517df71dfe42cb979aacdc454225cc.jpg, createdBy=0c532181739, createdName=12074e34m25(暂无昵称), createdTime=Mon Nov 23 23:25:56 CST 2020, time=2020-11-23, status=1, ipAttribution=)]
    2021-03-15 lpengcheng7

    谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2099583, encodeId=dcf1209958367, content=很有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210420/09716af288084795ba128059da55a818/c3137a18601c4c54bb7d71ac97630870.jpg, createdBy=e9985480565, createdName=ozzy, createdTime=Thu Nov 10 11:26:55 CST 2022, time=2022-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=969204, encodeId=98e896920411, content=好文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210528/a0d2a11691b24091b5b9dbfbadf81dc9/2fdf08a8d767479e869c7752c34716dc.jpg, createdBy=c3915509274, createdName=Ineslou, createdTime=Fri May 28 13:38:41 CST 2021, time=2021-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=948369, encodeId=a6889483695e, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef3e5469300, createdName=lpengcheng7, createdTime=Mon Mar 15 15:32:09 CST 2021, time=2021-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901610, encodeId=b2aa90161032, content=好好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210906/e141ddca670e4042bffbf47e00f8d2fd/b6517df71dfe42cb979aacdc454225cc.jpg, createdBy=0c532181739, createdName=12074e34m25(暂无昵称), createdTime=Mon Nov 23 23:25:56 CST 2020, time=2020-11-23, status=1, ipAttribution=)]
    2020-11-23 12074e34m25(暂无昵称)

    好好

    0

相关指南

2017 WFSBP指南：单相抑郁障碍的药物治疗

世界生物精神病学会联合会(WFSBP,World Federation of Societies of Biological Psychiatry) · 2017-04-03

2016 EULAR建议：应用合成的和生物类改善病情的抗风湿药物治疗类风湿性关节炎（更新版）

欧洲抗风湿病联盟(EULAR,The European League Against Rheumatism) · 2017-03-06

2017 AASM临床实践指南：成人慢性失眠的药物治疗

美国睡眠医学会(AASM,American Academy of Sleep Medicine) · 2017-02-01

2015 AGA指南：显微镜性结肠炎的药物治疗

美国胃肠病协会(AGA,American Gastroenterological Association) · 2015-11-14

2016 ACP临床实践指南：药物治疗与非药物治疗治疗成人重度抑郁症

美国医师协会(ACP,American College of Physicians) · 2016-02-09

2016 ACC/AHA/HFSA临床指南：新药物治疗心力衰竭

美国心脏协会(AHA,American Heart Association) · 2016-05-20